JP2016529484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529484A5 JP2016529484A5 JP2016521841A JP2016521841A JP2016529484A5 JP 2016529484 A5 JP2016529484 A5 JP 2016529484A5 JP 2016521841 A JP2016521841 A JP 2016521841A JP 2016521841 A JP2016521841 A JP 2016521841A JP 2016529484 A5 JP2016529484 A5 JP 2016529484A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- fra
- therapeutic agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 23
- 229940124597 therapeutic agent Drugs 0.000 claims 22
- 102000010451 Folate receptor alpha Human genes 0.000 claims 18
- 108050001931 Folate receptor alpha Proteins 0.000 claims 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 16
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 9
- 102100023123 Mucin-16 Human genes 0.000 claims 9
- 229910052697 platinum Inorganic materials 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 229940123237 Taxane Drugs 0.000 claims 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 6
- 229960001592 paclitaxel Drugs 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229950009929 farletuzumab Drugs 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 3
- 238000009093 first-line therapy Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 2
- 238000012286 ELISA Assay Methods 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims 2
- 230000000951 immunodiffusion Effects 0.000 claims 2
- 238000010166 immunofluorescence Methods 0.000 claims 2
- 238000001114 immunoprecipitation Methods 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 238000003127 radioimmunoassay Methods 0.000 claims 2
- 238000001262 western blot Methods 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229960005500 DHA-paclitaxel Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 claims 1
- 229960001573 cabazitaxel Drugs 0.000 claims 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- DXOJIXGRFSHVKA-BZVZGCBYSA-N larotaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 DXOJIXGRFSHVKA-BZVZGCBYSA-N 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000000405 serological effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837543P | 2013-06-20 | 2013-06-20 | |
| US61/837,543 | 2013-06-20 | ||
| PCT/US2014/043402 WO2014205342A2 (en) | 2013-06-20 | 2014-06-20 | Methods for treatment of ovarian cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529484A JP2016529484A (ja) | 2016-09-23 |
| JP2016529484A5 true JP2016529484A5 (cg-RX-API-DMAC7.html) | 2017-08-03 |
| JP6383787B2 JP6383787B2 (ja) | 2018-08-29 |
Family
ID=52105530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521841A Expired - Fee Related JP6383787B2 (ja) | 2013-06-20 | 2014-06-20 | 卵巣癌の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20160311921A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3011013A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6383787B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014284212B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015031950A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2914237A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015017950A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014205342A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009521206A (ja) * | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| IL257531B2 (en) * | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| WO2019099374A2 (en) * | 2017-11-14 | 2019-05-23 | University Of Virginia Patent Foundation | Compositions and methods for making and using bispecific antibodies |
| MX2020009522A (es) | 2018-03-13 | 2020-10-22 | Phanes Therapeutics Inc | Anticuerpos anti-folato del receptor 1 y usos de los mismos. |
| US20230074385A1 (en) * | 2019-12-23 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Method for producing eribulin-based antibody-drug conjugate |
| CN117741149A (zh) * | 2024-02-19 | 2024-03-22 | 卡秋(江苏)生物科技有限公司 | 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| US6351666B1 (en) | 1998-02-27 | 2002-02-26 | Biofield Corp. | Method and apparatus for sensing and processing biopotentials |
| JP3952599B2 (ja) | 1998-07-16 | 2007-08-01 | 松下電器産業株式会社 | 映像表示装置および映像表示方法 |
| CN1277779A (zh) | 1998-07-16 | 2000-12-20 | 艾马热蒂有限公司 | 图像标识和分送系统 |
| US6694090B1 (en) | 1998-07-20 | 2004-02-17 | Thomson Licensing S.A. | Method and apparatus for dynamically overriding a ratings limit during playback of a digital program |
| JP4322426B2 (ja) | 1998-07-21 | 2009-09-02 | エヌエックスピー ビー ヴィ | データキャリヤから得たデータを少なくとも１つの他の補助キャリヤ信号によってステーションに送信するシステム |
| IT1303624B1 (it) | 1998-07-22 | 2000-11-15 | Techint Spa | Dispositivo per elettrodeposizione a cella circonferenziale a flussidifferenziati. |
| DE19833226C1 (de) | 1998-07-23 | 2000-04-20 | Steuler Industriewerke Gmbh | Niederschlagsrohrbündel für Naßelektrofilter |
| AU5311599A (en) | 1998-07-24 | 2000-02-14 | Ce Resources Pte Ltd | Array electrophoretic apparatus |
| IT1301872B1 (it) | 1998-07-24 | 2000-07-07 | Abb Adda S P A | Dispositivo di comando e controllo di interruttori di alta e mediatensione |
| AU8662898A (en) | 1998-07-24 | 2000-02-14 | Procter & Gamble Company, The | Inner bag-type package having pump dispenser with improved dip tube |
| DE19833340A1 (de) | 1998-07-24 | 2000-02-10 | Karlsruhe Forschzent | Wurmförmiger Arbeitsmechanismus |
| CA2338369C (en) | 1998-07-24 | 2005-04-05 | Yoshino Kogyosho Co., Ltd. | Vessel equipped with a manual pump |
| EP1501522A4 (en) * | 2002-05-06 | 2007-12-05 | Univ Utah Res Found | PRE-BLOCKING WITH NON-HA GAGS INCREASES THE EFFECTIVENESS OF HA-CONJUGATED CANCER |
| US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| JP2008547028A (ja) * | 2005-06-24 | 2008-12-25 | サイファージェン バイオシステムズ， インコーポレイテッド | 卵巣癌用のバイオマーカー |
| US8986650B2 (en) * | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| WO2008075330A1 (en) * | 2006-12-20 | 2008-06-26 | J-C Health Care Ltd. | Method for administration of pegylated liposomal doxorubicin |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| RU2630608C2 (ru) * | 2010-11-05 | 2017-09-11 | Морфотек Инк. | Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа |
| PL2731972T3 (pl) | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
| CN104755498B (zh) * | 2012-08-31 | 2019-06-18 | 伊缪诺金公司 | 用于检测叶酸受体1的诊断测定和试剂盒 |
-
2014
- 2014-06-20 BR BR112015031950A patent/BR112015031950A2/pt not_active Application Discontinuation
- 2014-06-20 JP JP2016521841A patent/JP6383787B2/ja not_active Expired - Fee Related
- 2014-06-20 AU AU2014284212A patent/AU2014284212B2/en not_active Ceased
- 2014-06-20 US US14/898,905 patent/US20160311921A1/en not_active Abandoned
- 2014-06-20 WO PCT/US2014/043402 patent/WO2014205342A2/en not_active Ceased
- 2014-06-20 MX MX2015017950A patent/MX2015017950A/es unknown
- 2014-06-20 EP EP14813679.9A patent/EP3011013A4/en not_active Withdrawn
- 2014-06-20 CA CA2914237A patent/CA2914237A1/en not_active Abandoned
-
2019
- 2019-03-19 US US16/357,577 patent/US20190202930A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529484A5 (cg-RX-API-DMAC7.html) | ||
| AU2011281700B2 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer | |
| US20130121999A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| Spiegelberg et al. | The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells | |
| KR20140094594A (ko) | 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커 | |
| EP3464369A1 (en) | Anti-pd-1 antibody for use in a method of treating a tumor | |
| WO2014205342A4 (en) | Methods for treatment of ovarian cancer | |
| RU2017136863A (ru) | Способы лечения рака легкого | |
| Yau et al. | Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma | |
| JP2018516244A5 (cg-RX-API-DMAC7.html) | ||
| Zhou et al. | Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer | |
| Kim et al. | Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer | |
| EP3216460B1 (en) | Antigen polypeptide for detecting plasma immunological marker-vegfr1 autoantibody and use thereof | |
| Wang et al. | Fork head box M1 regulates vascular endothelial growth factor-A expression to promote the angiogenesis and tumor cell growth of gallbladder cancer | |
| Sun et al. | Expression of annexin A5 in serum and tumor tissue of patients with colon cancer and its clinical significance | |
| KR102159538B1 (ko) | 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도 | |
| WO2021229293A2 (en) | Endogenous retroviruses for the detection, diagnosis, and prognosis of cancer | |
| US20230190752A1 (en) | Compositions and methods for predicting therapeutic outcome | |
| CN121175569A (zh) | Pro-c5测定 | |
| RU2014110270A (ru) | Способ прогнозирования риска гипертензии, связанной с антиангиогенной терапией | |
| HK1184854B (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |